Jiangsu Hengrui Medicine stock
600276.SSSHHJiangsu Hengrui Medicine Co., Ltd., HealthcareISIN CNE0000014W7
69Score 69 out of 100, Neutral
Price and trend
55 / 100
Price history
−23% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 8.2% below it.
Since February 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 55).
The price is 26% below its 52-week high. Largest decline in 20 years: 71% (December 2020 to April 2022).
Chart figures for advanced users
- SMA 50$6.96
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.83
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)55
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.40
- The lowest closing price of the last twelve months.
- Resistance$9.68
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Jiangsu Hengrui Medicine Co., Ltd. belongs to the Drug Manufacturers (Specialty & Generic) industry (China) and, with a market value of $45.85B, is number 6 of 77 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.71B (up 12.3% year on year) and earnings of $1.16B (up 21.7%).
- For fiscal 2026, analysts expect on average revenue of $5.03B (up 6.7%) and adjusted earnings per share of $0.21 (up 16.2%).
Show more
- MEQIRI Score 69 out of 100 (Neutral): rank 148 of 702 in Healthcare, median 53.
- The P/E is 35.6 (Drug Manufacturers (Specialty & Generic) median 32.5, own median of recent years 57.2).
- Our model puts fair value at $9.84, with the price 27% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 33.3% in fiscal 2025, Drug Manufacturers (Specialty & Generic) median 11.3%.Profitability 90
- More cash than debtCash $6.53B, financial debt $63.23M.Stability 90
- Reliable dividendNo dividend cut for 24 years.Capital allocation 73
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are profitability and stability, while momentum holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 70 to 69.
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $7.57 and expensive above $14.05 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $13.11 (cash-flow model) and $6.57 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $8.59, at 6.3% it would be $11.72.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (32.5).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 6% on the twelve months before. Revenue has grown strongly since 2006, at around 18% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 85%, operating 26%, net 25%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 19 Apr 2027in 157 days
- Last reported
- 27 Oct 2026EPS reported $0.05 (expected $0.05)above expectations
Analyst estimates
Earnings estimates have barely changed since 28 Oct 2026.
- Earnings per share
- $0.21+0.6%
- Revenue
- $5.03B−0.1%
- Earnings per share
- $0.23+0.4%
- Revenue
- $5.69B−0.7%
MEQIRI has stored the estimates since 28 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Jiangsu Hengrui Medicine
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Takeda PharmaceuticalTAK $68.52B57
- Galderma GroupGALD.SW $54.41B64
- Teva Pharmaceutical IndustriesTEVA $50.93B54
- Sun Pharmaceutical IndustriesSUNPHARMA.NS $48.07B72
- Sandoz GroupSDZ.SW $45.13B66
- Jiangsu Hengrui Pharmaceuticals1276.HK $42.06B67
- HaleonHLN $39.95B61
- ZoetisZTS $33.71B75
ETFs that hold Jiangsu Hengrui Medicine
Held by 54 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Harvest CSI300 UCITS ETF 1DRQFI | 0.98% | 0.65% | €251.68M |
| HSBC MSCI China A UCITS ETF USDH41K | 0.92% | 0.30% | €68.31M |
| Xtrackers Harvest CSI A500 UCITS ETF 1DAH50 | 0.87% | 0.65% | €10.81M |
Show 5 more
| Amundi MSCI Emerging Markets SRI Climate Paris Aligned UCITS ETF DR (C)AMEI | 0.61% | 0.25% | €2.64B |
| UBS Solactive China Technology UCITS ETF USD accUIC2 | 0.45% | 0.47% | €254.2M |
| Market Access Stoxx China A Minimum Variance Index UCITS ETFM9SV | 0.39% | 0.45% | €284.44M |
| Amundi MSCI China ESG Selection Extra UCITS ETF AccLCHI | 0.22% | 0.65% | €564.13M |
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.19% | 0.30% | €132.6M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 13 Nov 2026, previously Strong
- Valuation signal Undervalued since 11 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.